Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Institute of Hematology, Zhejiang University, Hangzhou, China.
Bone Marrow Transplant. 2019 Dec;54(12):2072-2080. doi: 10.1038/s41409-019-0625-y. Epub 2019 Aug 5.
Chimeric antigen receptor (CAR) T-cell therapy has displayed potent anti-leukemia activity in acute lymphocytic leukemia (ALL), acting as a new ray of hope to refractory/relapsed patients. However, the influence of CAR-T therapy on host immune system has not been well elucidated. Thus, We applied high-throughput T cell receptor β chain sequencing to track the dynamic change of T-cell repertoire induced by CAR-T therapy in B-cell ALL patients. Six Chinese patients achieving complete remission were under observation, whose blood samples, bone marrow samples and infused CAR-T samples were collected at serial time points before and after CAR-T therapy. We observed decreased TCR diversity and increased clonality of T-cell repertoire in both peripheral blood and bone marrow after CAR-T administration. The persistent T cell clones in blood and bone marrow expanded following leukemic cell destruction and were barely detected in CAR T-cell pool. For the first time, our results demonstrated CAR-T therapy could stimulate the clonal proliferation of CAR-negative T cells in patients. Considering other groups' animal results indicating that CAR-T therapy could facilitate the proliferation of tumor antigen-specific T cells and that the emergence of these T cell clones followed the destruction of leukemic cells, they are most likely tumor antigen-specific.
嵌合抗原受体 (CAR) T 细胞疗法在急性淋巴细胞白血病 (ALL) 中显示出强大的抗白血病活性,为难治/复发患者带来了新的希望。然而,CAR-T 疗法对宿主免疫系统的影响尚未得到充分阐明。因此,我们应用高通量 T 细胞受体β链测序来跟踪 CAR-T 疗法在 B 细胞 ALL 患者中诱导的 T 细胞 repertoire 的动态变化。我们观察到在 CAR-T 给药后,外周血和骨髓中的 TCR 多样性降低,T 细胞 repertoire 的克隆性增加。在白血病细胞破坏后,血液和骨髓中持续存在的 T 细胞克隆扩增,而在 CAR-T 细胞池几乎检测不到。我们的研究结果首次表明,CAR-T 疗法可以刺激患者中 CAR 阴性 T 细胞的克隆增殖。考虑到其他研究小组的动物实验结果表明,CAR-T 疗法可以促进肿瘤抗原特异性 T 细胞的增殖,并且这些 T 细胞克隆的出现紧随白血病细胞的破坏,它们很可能是肿瘤抗原特异性的。